Cargando…
Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma
Hemangiopericytoma is a rare disease entity of soft-tissue sarcoma (STS) that can be cured with surgical resection. In cases of inoperable recurrence or metastasis, palliative chemotherapy is indicated, though there is currently no approved chemotherapy regimen. Therefore new treatment regimens are...
Autores principales: | Lee, Su Jin, Kim, Seung Tae, Park, Se Hoon, Choi, Yoon La, Park, Jae Berm, Kim, Sung-Joo, Lee, Jeeyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179434/ https://www.ncbi.nlm.nih.gov/pubmed/25276340 http://dx.doi.org/10.1186/2045-3329-4-13 |
Ejemplares similares
-
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study
por: Kim, Hyun-Jun, et al.
Publicado: (2018) -
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
por: Kim, Hee Kyung, et al.
Publicado: (2016) -
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
por: Yoo, Kwai Han, et al.
Publicado: (2015) -
The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018) -
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)